Latest Breaking News On - Quanta therapeutics inc - Page 1 : vimarsana.com

The existence of two approved therapies, Lumakras (sotorasib, Amgen Inc.) and Karzati (adagrasib, Mirati Therapeutics Inc.), has been a triumphant success against KRAS, a protein that was once considered undruggable. KRAS is the most frequently mutated oncogene in solid tumors. KRAS driver mutations are found in about 30% of non-small-cell lung cancers (NSCLC), about half of colorectal cancers, and more than 90% of pancreatic cancers. Lumakras and Karzati both target the G12C mutation. Inhibitors that target other mutations, like G12D, are now making their way through preclinical and clinical development, while some companies are developing therapies that would target mutated KRAS more broadly, irrespective of the specific mutation that is activating the protein.

Mirati therapeutics incAmgen incBioworld scienceRevolution medicines incPancreatic cancerNon small cell lung cancerElicio therapeutics incQuanta therapeutics incMolecular gluesColon cancerRmc 6236Nested therapeutics incEli 002Tri complex inhibitorsQtx 3544Nst 628